Clinical use of ACQUIRE Therapy for Children Diagnosed With CASK-Gene Related Disabilities

Simple item page
dc.contributor.authorWallace, Dory A.en
dc.contributor.authorTrucks, Mary Rebekahen
dc.contributor.authorDeLuca, Stephanie C.en
dc.date.accessioned2025-03-13T15:38:03Zen
dc.date.available2025-03-13T15:38:03Zen
dc.date.issued2024-11en
dc.descriptionThis work was internally funded by the Fralin Biomedical Research Institute Neuromotor Research Clinic (FBRINMRC).en
dc.description.abstractObjective: To report practice based evidence built on clinical findings where an intensive therapeutic approach called ACQUIRE Therapy was used as a rehabilitation/habilitation tool for children diagnosed with CASK mutations. ACQUIRE Therapy delivery is based on principles of learning and guided by a therapeutic framework often used in the delivery of intensive therapy. Design: Clinical Cohort. Setting: Natural environments (e.g., home-like environment). Participants: A total of 20 females, 12 to 128 months, mean age = 44.75 (SD = 31.64). Intervention: Trained Occupational therapists delivered high-dosage rehabilitation for an average of 64.06 hours (SD = 12.91) across 4 weeks. ACQUIRE Therapy targeted cross-domain intervention targets often associated with executive control and praxis. Main outcome measures: Clinical data was examined from the following sources; therapist daily treatment documentation (eg, therapy goals, video recordings, daily therapy logs, and discharge documentation). Results: Receptive communication improved in all children. The most common motor skill improvements occurred in trunk control occurring in 33% of children; followed by, gross reaching abilities in 21% of children; fine-motor skills in 19%; head control in 15%; and mobility in 12%. Documentation of cognitive-motor pairing of skills was documented in all children. Conclusions: Diagnosis specific intervention targets (eg, attention and cognitive-pairing skills) need to be considered when providing therapeutic services to children with CASK-gene mutations and other forms of Global Developmental Delay.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1177/27536351241302852en
dc.identifier.urihttps://hdl.handle.net/10919/124851en
dc.identifier.volume13en
dc.language.isoenen
dc.publisherSageen
dc.rightsCreative Commons Attribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectCASK-gene mutationen
dc.subjectmicrocephalyen
dc.subjectACQUIRE therapyen
dc.subjectIntensive therapyen
dc.subjectintensive rehabilitationen
dc.subjectglobal developmental delayen
dc.titleClinical use of ACQUIRE Therapy for Children Diagnosed With CASK-Gene Related Disabilitiesen
dc.title.serialAdvances in Rehabilitation Science and Practiceen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
wallace-et-al-2024.pdf
Size:
523.38 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.5 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Scholarly Works, Fralin Biomedical Research Institute at VTC